Skip to main content

Table 5 Clinical response to anti-EGFR therapy in KRAS wild-type patients

From: Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia

  

KRASwt

 

KRASwt (N = 118)

PI3Kwt (N = 89)

PI3Kmut (N = 29)

PR

35 (30%)

28 (31%)

7 (24%)

SD

58 (49%)

45 (51%)

13 (45%)

PD

25 (21%)

16 (18%)

9 (31%)

  1. PR, partial response; SD, stable disease; PD, progression disease. wt, wild-type.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us